
Saw

The DMS. 930 defibrillator/Monitor is portable, compact, modular, and has been specially designed for emergencies in the field, during transport and in the hospital. It is microprocessor based and has a unique detachable, lightweight ECG monitor. Full documentation is provided via a high resolution matrix printer. In addition to being an advanced defibrillator DMS 930 will operate as a bedside ECG monitor or as a complete, compact resuscitation unit.

In a field emergency you need equipment that is not only efficient and reliable, but quick and easy to use. The DMS 730 is just that. It is a lightweight, portable defibrillator/monitor with the added option of a non invasive temporary pacemaker, as shown here.

Simple 1-2-3 operation, large screen display, easy access controls, and proven performance enables immediate diagnosis with ECG picked up by the paddles or by normal ECG electrodes.

The Modura Rail Trolleys give mobility to a whole range of medical equipment products. The ladder arrangement enables the user flexibility for mounting both Modura Rail accessories and patient monitoring equipment. Other uses are for Resuscitation Trolleys, Anaesthetic Storage Trolleys and Treatment Trolleys in high dependency non-hazardous areas, as well as in general ward areas.






SaW Vickers

S&W Vickers Ltd, Ruxley Corner, Sidcup, Kent DA14 5BL

Telephone: 01-309 0433 Telex: 896328 Fax: 01-309 0919



Arythmol is an important antiarrhythmic agent, new to the United Kingdom. Its proven efficacy and favourable side effect profile¹ make Arythmol an important consideration when treating ventricular arrhythmias, even in selected patients with poor left ventricular function.²

References: 1 Singh BN et al, Am Heart J 1988: 116: 1542-1550. 2 Baker BJ et al. J Electrophysiol 1987; 1: 527-535.

propafenone HCl

knoll BASF Group

▼ ABBREVIATED PRESCRIBING INFORMATION Presentation White, film coated 150mg and 300mg tablets containing propafenone hydrochloride. Indications Prophylaxis and treatment of ventricular arrhythmias. Dose Individual maintenance dose should be determined under cardiological surveillance and hospital conditions. Adults Initially 150mg three times daily increasing at a minimum of 3 day intervals to 300mg twice daily and, if necessary, to a maximum of 300mg three times daily. Elderly patients: patients with impaired hepatic or renal function A reduction in the recommended dose is advisable. Contraindications Uncontrolled heart failure, cardiogenic shock (except arrhythmia induced), bradycardia, uncontrolled electrolyte disturbances, severe obstructive pulmonary disease, marked hypotension. Unless adequately paced, ARYTHMOI, should not be used in the presence of sinus node dysfunction, atrial conduction defects, second degree or greater atrioventricular block, bundle branch or distal block. Precautions The minor negative inotropic effect of ARYTHMOL may assume importance in patients predisposed to heart failure. Effects of ARYTHMOL may be potentiated if given with other local anaesthetic type agents or agents which depress myocardial activity. Reduced doses of digoxin, warfain, propranolol and metoprolol may be required when given in combination with ARYTHMOL, Plasma levels of ARYTHMOL may be increased by concomitant administration of cinetidine or quindine. ARYTHMOL has been shown to decrease pacemaker sensitivity and increase pacing thresholds. ARYTHMOL, should not be used during pregnancy. Side effects Generally well tolerated. Minor side effects also also proarrhythmic effects of the nervous system and cardiovascular system. Dizziness, nausea, vomiting, fatigue, bitter taste, constipation, diarrhoea, head-ache, blurred vision, dry mouth may occur. More rarely, bypersensitivity reactions (e.g. skin rash, cholestasis, blood dyscrasias, lupus syndrome) and seizures may occur. All side effects are reversible on disco